Therapy News and Research

RSS

OA patients benefit from walking skills training following total hip arthroplasty

Researchers in Norway report that patients who receive walking skills training following total hip arthroplasty for osteoarthritis show improved physical function. The physical therapy program displayed a positive effect on walking distance and stair climbing which continued 12 months following hip replacement surgery.

15 Dec 2011

Vaginal progesterone reduces rate of preterm birth and neonatal complications

A team of investigators of the National Institutes of Health housed at the Detroit Medical Center (DMC) and Wayne State University (WSU) published today that performing a cervical ultrasound in all pregnant women and treating those with a short cervix with vaginal progesterone reduces the rate of preterm birth and neonatal complications.

15 Dec 2011

Mayo Clinic to build new cancer treatment facility

Mayo Clinic broke ground today for a cutting edge cancer therapy facility at its Phoenix campus. Construction begins this month on a $182 million facility to house Mayo Clinic's Proton Beam Therapy program - marking the beginning of a new era in cancer treatment.

15 Dec 2011

Researchers identify genetic factors responsible for neurons in the thalamus

The thalamus is the central translator in the brain: Specialized nerve cells (neurons) receive information from the sensory organs, process it, and transmit it deep into the brain. Researchers from the Institute of Toxicology and Genetics (ITG) of KIT have now identified the genetic factors Lhx2 and Lhx9 responsible for the development of these neurons.

15 Dec 2011

FDA approves modernized labeling for ViroPharma's Vancocin Capsules

ViroPharma Incorporated today announced the modernization of labeling for Vancocin (vancomycin hydrochloride, USP) Capsules made effective through the U.S. Food and Drug Administration's (FDA) approval of a supplemental new drug application.

15 Dec 2011

JHN to initiate new Phase I immunotherapy trial in glioblastoma

Physicians at the Jefferson Hospital for Neuroscience (JHN), the region's only dedicated hospital for neuroscience, are tackling a particularly aggressive brain cancer that even surgery, chemotherapy and radiation often fail to treat with a promising new immunotherapy to attack a patient's tumor with their own cancer cells.

15 Dec 2011

Stereotactic ablative radiotherapy may eradicate cancer

An innovative treatment technology could give cancer patients new hope for survival. In an international study based at Lawson Health Research Institute and London Health Sciences Centre's London Regional Cancer Program (LRCP), scientists are testing a therapy with the potential to eradicate cancers previously thought to be incurable.

15 Dec 2011

MDC professor to receive Gottfried Wilhelm Leibniz Prize

Professor Nikolaus Rajewsky of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin is to receive Germany's most prestigious research award, the Gottfried Wilhelm Leibniz Prize.

15 Dec 2011

Fast Forward, Lineagen to fund clinical development and validation of blood-based assay for MS

Lineagen, Inc., an innovative molecular diagnostics company focused on complex, genetically linked disorders, and Fast Forward, LLC, a nonprofit subsidiary of the National Multiple Sclerosis Society, today announced an alliance to fund the clinical development and validation of a blood-based assay for multiple sclerosis.

15 Dec 2011

Ganitumab shows promise in early-phase trials for metastatic pancreatic cancer

Over 17,000 patients will have been diagnosed with locally-advanced pancreatic cancer in the United States in 2011. Surgery is not a treatment option for these patients whose tumor has grown beyond the pancreas to surrounding vital structures.

15 Dec 2011

National conference on mindfulness for children

Beginning February 4, 2012, the UC San Diego Center for Mindfulness will host a national conference for teachers, parents, therapists, and school administrators called Bridging the Hearts & Minds of Youth. The two-day conference is designed to familiarize and train attendees with the ways in which mindfulness is being taught to children and teens in a variety of settings.

15 Dec 2011

Novel prognostic model for patients with treatment-related MDS

A large-scale analysis of patients whose myelodysplastic syndrome is related to earlier cancer treatment overturns the notion that all of them have a poor prognosis, researchers from The University of Texas MD Anderson Cancer Center report at the 53rd Annual Meeting of the American Society of Hematology.

15 Dec 2011

Molecular signature indicative of hypoxia predicts progression to AD

A study led by Research Professor Matej Ore-ič from VTT Technical Research Centre of Finland suggests that Alzheimer's disease is preceded by a molecular signature indicative of hypoxia and up-regulated pentose phosphate pathway.

15 Dec 2011

Initiative for Women with Disabilities opens new facility in Manhattan

The Initiative for Women with Disabilities Elly and Steve Hammerman Health & Wellness Center (IWD) at NYU Langone Medical Center opened the doors to a new 4,200-square-foot facility located at 359 Second Avenue in Manhattan.

14 Dec 2011

Chronic fatigue syndrome may be reason behind many school absenteeism: Study

According to a new study one in 100 secondary school pupils could be missing classes because of chronic fatigue syndrome, also known as Myalgic Encephalomyelitis (ME). A study following 2,855 pupils at three schools, published in the online journal BMJ Open, found 28 missed school with chronic fatigue syndrome.

14 Dec 2011

Fresh cells can pep talk immune cells exhausted by HIV or hepatitis C

Chronic infections by viruses such as HIV or hepatitis C eventually take hold because they wear the immune system out, a phenomenon immunologists describe as exhaustion.

14 Dec 2011

$Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL$

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG), announced final results from a phase II investigational study evaluating the combination of REVLIMID® (lenalidomide) and rituximab in 59 patients with relapsed or refractory chronic lymphocytic leukemia (CLL). These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.

14 Dec 2011

Children of childhood cancer survivors do not have increased risk for birth defects

A large, retrospective study of the children of childhood cancer survivors who were treated with radiation therapy and/or some forms of chemotherapy found that the offspring do not have an increased risk for birth defects compared to children of cancer survivors who did not receive such treatments.

14 Dec 2011

Promising results from Fate Therapeutics' ProHema Phase 1b trial on hematologic malignancies

Fate Therapeutics, Inc. announced today promising clinical results from a Phase 1b trial of ProHema (FT1050-enhanced umbilical cord blood) as part of double-umbilical cord blood (UCB) transplants in adult patients with hematologic malignancies who have undergone reduced-intensity conditioning therapy.

14 Dec 2011

CTI, Chroma announce final results from tosedostat phase II study on AML

Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. announced that final results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) were presented by Jorge Cortes, M.D. of the University of Texas M.D. Anderson Cancer Center during the Acute Myeloid Leukemia - Therapy, excluding Transplantation: Clinical Studies session at the American Society of Hematology Annual Meeting.

14 Dec 2011